Please login to the form below

Not currently logged in
Email:
Password:

Sanofi and Merck & Co finalise vaccine alliance split

Dissolve Sanofi Pasteur MSD after poor sales growth

Sanofi Pasteur MSDMerck & Co and Sanofi have finalised the dissolution of their joint vaccines venture, Sanofi Pasteur MSD.

The former partners will now separately pursue vaccine development strategies for European patients, integrating their respective pipeline pursuits and products from the venture into their primary vaccines portfolios.

After over 20 years of business, the break-up came in the wake of poor growth, with Sanofi Pasteur MSD only bringing in sales of €824m in 2015 - less than a fifth of Sanofi's year-end vaccines sales of €4.7bn.

Each firm has a number of promising projects in the pipeline, with Sanofi and its vaccines unit Sanofi Pasteur focusing on vaccines for yellow fever, Japanese encephalitis and dengue virus.

The French company also began research for a potential Zika vaccine in February last year.

Meanwhile, Merck & Co (known as MSD outside of North America) is expected to launch its Ebola vaccine this year after a phase III trial of 4,000 patients saw 100% efficacy after a single dose.

World Health Organization vaccines specialist Marie Paule Kieny said that the trial results were a “game-changer” for patients and for fighting future outbreaks of the virus.

In a joint statement, Sanofi and Merck said: “We are proud of Sanofi Pasteur MSD's successful 20-year history.

“Our joint venture has achieved considerable success over the past two decades from a public health and commercial perspective.

“We believe that focusing our efforts on opportunities unique to our respective companies will better position us to drive growth, execute in a more efficient manner and optimise vaccine coverage.”

Article by
Rebecca Clifford

4th January 2017

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....